34545-20-5

Basic information

• Product Name: 3-BROMO-4-METHYL-5-NITROBENZOIC ACID
• Synonyms: Benzoic acid, 3-broMo-4-Methyl-5-nitro-
• CAS NO: 34545-20-5
• Molecular Formula: C₈H₆BrNO₄
• Molecular Weight: 260.04154
• Mol File: 34545-20-5.mol

Chemical Properties

• Boiling Point: 387°C at 760 mmHg
• Flash Point: 187.9°C
• Appearance: /
• Density: 1.777g/cm³
• Vapor Pressure: 1.11E-06mmHg at 25°C
• Refractive Index: 1.633
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-BROMO-4-METHYL-5-NITROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-METHYL-5-NITROBENZOIC ACID(34545-20-5)
• EPA Substance Registry System: 3-BROMO-4-METHYL-5-NITROBENZOIC ACID(34545-20-5)

Safety Data

• Hazardous Substances Data: 34545-20-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Bromo-4-methyl-5-nitrobenzoic acid is used as a building block in organic synthesis for the creation of various complex organic compounds. Its unique structure and functional groups facilitate the formation of new chemical entities, contributing to the advancement of organic chemistry.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-Bromo-4-methyl-5-nitrobenzoic acid is utilized as a reagent in the preparation of pharmaceutical compounds. Its strong nitro group allows for the synthesis of a wide range of drug candidates, enhancing the development of novel therapeutic agents.
Used in Drug Development:
3-Bromo-4-methyl-5-nitrobenzoic acid is studied for its potential applications in the development of new drugs. Its unique chemical properties and reactivity make it a promising candidate for the design and synthesis of innovative pharmaceuticals, addressing unmet medical needs.
Used in Material Science:
3-Bromo-4-methyl-5-nitrobenzoic acid also has potential applications in the field of material science. Its chemical structure and properties can be exploited to develop new materials with specific characteristics, such as improved stability, reactivity, or selectivity, for various industrial applications.

InChI:InChI=1/C8H6BrNO4/c1-4-6(9)2-5(8(11)12)3-7(4)10(13)14/h2-3H,1H3,(H,11,12)

Upstream product

• 54591-62-7 3-amino-4-methyl-5-nitrobenzoic acid 
• 16533-71-4 3,5-dinitro-p-toluic acid 
• 96-98-0 4-methyl-3-nitrobenzoic acid 

Downstream Products

• 72623-34-8 3-bromo-5-(hydroxymethyl)-2-methylnitrobenzene 
• 223519-08-2 methyl 3-bromo-4-methyl-5-nitrobenzoate 
• 1285532-20-8 C₂₁H₂₅N₅O 
• 1285531-68-1 1-(4-(6-(N-(2-(piperidin-1-yl)ethyl)aminocarbonyl)-1H-indazol-4-yl)phenyl)-3-(3-(trifluoromethoxy)phenyl)urea 
• 885518-47-8 methyl 4-bromo-1H-indazole-6-carboxylate 
• 885523-43-3 4-bromo-1H-indazole-6-carboxylic acid 
• 223519-11-7 methyl 3-amino-5-bromo-4-methylbenzoate 
• 1527007-77-7 methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-6-carboxylate 
• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 
• 885518-53-6 4-bromo-1H-indazol-6-amine 
• 1638772-21-0 methyl 4-bromo-2-methyl-2H-indazole-6-carboxylate 
• 1638759-79-1 methyl 4-bromo-1-methyl-1H-indazole-6-carboxylate 
• 356082-44-5 2-bromo-6-nitroterephthalic acid 

Relevant articles and documents

SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell pr

CARBOXY SUBSTITUTED (HETERO) AROMATIC RING DERIVATIVES AND PREPARATION METHOD AND USES THEREOF

Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.

Synthesis of substituted 4-(1H-indol-6-yl)-1H-indazoles as potential PDK1 inhibitors

The development of a preparative route to a series of novel 4-(1H-indol-6-yl)-1H-indazole compounds as potential PDK1 inhibitors is described. The synthetic strategy centres on the late-stage Suzuki cross-coupling of N-unprotected indazole and indole frag

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly di

PROLYL HYDROXYLASE INHIBITORS

The invention described herein relates to certain 2,4-dioxo-l,2,3,4-tetrahydro-7- quinazolinecarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Studies on the Synthesis of Substituted Phenanthrenoids

Highly regioselective reactions for the construction of polysubstituted benzenes 18, 19, 20, 22, 24, and 44-47 are described, including some remarkable site-selective halogenations.These have been employed in the synthesis of halo-, nitro-, amino-, and urethane-substituted stilbenes 37, 38, and 51-56.Ideas for thermal as well as photochemical cyclizations are presented and explored.Stilbene 54 led to the formation of phenanthrenes 57, 58, and 62; likewise 55 furnished two new tricyclics, 60 and 61, whereas irradiation of 52 in tert-butylalcohol captured solvent to produce phenanthrenes 63 and 64.Strategies for the total synthesis of juncusol (1), a cytotoxic phytoalexin, are considered.